Sihuan Pharmaceutical Holdings Group Yönetim
Yönetim kriter kontrolleri 4/4
Sihuan Pharmaceutical Holdings Group CEO'su Weicheng Guo, Oct2014 tarihinde atandı, in görev süresi 10.08 yıldır. in toplam yıllık tazminatı CN¥ 3.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.12% ine doğrudan sahiptir ve bu hisseler HK$ 8.29M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.1 yıl ve 8.7 yıldır.
Anahtar bilgiler
Weicheng Guo
İcra Kurulu Başkanı
CN¥3.0m
Toplam tazminat
| CEO maaş yüzdesi | 100.0% |
| CEO görev süresi | 10.1yrs |
| CEO sahipliği | 0.1% |
| Yönetim ortalama görev süresi | 2.1yrs |
| Yönetim Kurulu ortalama görev süresi | 8.7yrs |
Son yönetim güncellemeleri
Recent updates
What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You
Oct 02
Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?
Sep 30Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year
May 31Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
May 27A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Dec 05Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Aug 19Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Apr 21Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?
Nov 03Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?
Jun 21Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Mar 09A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Nov 28Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now
Jun 22How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?
May 11Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit
Mar 30How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?
Mar 07Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?
Feb 07
Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Jan 11Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters
Dec 07CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥38m |
| Mar 31 2024 | n/a | n/a | -CN¥46m |
| Dec 31 2023 | CN¥3m | CN¥3m | -CN¥54m |
| Jun 30 2023 | n/a | n/a | -CN¥2b |
| Mar 31 2023 | n/a | n/a | -CN¥2b |
| Dec 31 2022 | CN¥3m | CN¥3m | -CN¥2b |
| Jun 30 2022 | n/a | n/a | -CN¥144m |
| Mar 31 2022 | n/a | n/a | CN¥141m |
| Dec 31 2021 | CN¥6m | CN¥6m | CN¥427m |
| Sep 30 2021 | n/a | n/a | CN¥681m |
| Jun 30 2021 | n/a | n/a | CN¥945m |
| Mar 31 2021 | n/a | n/a | CN¥727m |
| Dec 31 2020 | CN¥6m | CN¥6m | CN¥508m |
| Sep 30 2020 | n/a | n/a | -CN¥14m |
| Jun 30 2020 | n/a | n/a | -CN¥537m |
| Mar 31 2020 | n/a | n/a | -CN¥2b |
| Dec 31 2019 | CN¥6m | CN¥6m | -CN¥3b |
| Sep 30 2019 | n/a | n/a | -CN¥2b |
| Jun 30 2019 | n/a | n/a | -CN¥1b |
| Mar 31 2019 | n/a | n/a | CN¥238m |
| Dec 31 2018 | CN¥6m | CN¥6m | CN¥2b |
| Sep 30 2018 | n/a | n/a | CN¥1b |
| Jun 30 2018 | n/a | n/a | CN¥1b |
| Mar 31 2018 | n/a | n/a | CN¥1b |
| Dec 31 2017 | CN¥6m | CN¥6m | CN¥1b |
Tazminat ve Piyasa: Weicheng 'ın toplam tazminatı ($USD 418.80K ) Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 503.60K ).
Tazminat ve Kazançlar: Weicheng 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Weicheng Guo (60 yo)
10.1yrs
Görev süresi
CN¥3,000,000
Tazminat
Dr. Weicheng Guo co-founded Sihuan Pharmaceutical Holdings Group Ltd. and has been its Chief Executive Officer since October 20, 2014. Dr. Guo is responsible for the overall operations of Sihuan Pharmaceut...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 18.5yrs | CN¥7.00m | 5.34% HK$ 363.1m | |
| Deputy Chairman & CEO | 10.1yrs | CN¥3.00m | 0.12% HK$ 8.3m | |
| Deputy CEO | 2.1yrs | CN¥5.05m | Veri yok | |
| Executive Director | 4yrs | CN¥646.00k | 2.14% HK$ 145.3m | |
| Joint Company Secretary & Executive Director | 2.1yrs | CN¥1.77m | Veri yok | |
| Joint Company Secretary | 2.1yrs | Veri yok | Veri yok | |
| Deputy General Manager | no data | CN¥4.26m | Veri yok |
2.1yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş
Deneyimli Yönetim: 460 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 18.5yrs | CN¥7.00m | 5.34% HK$ 363.1m | |
| Deputy Chairman & CEO | 18.5yrs | CN¥3.00m | 0.12% HK$ 8.3m | |
| Deputy CEO | 2.1yrs | CN¥5.05m | Veri yok | |
| Executive Director | 6.6yrs | CN¥646.00k | 2.14% HK$ 145.3m | |
| Joint Company Secretary & Executive Director | 6.6yrs | CN¥1.77m | Veri yok | |
| Independent Non-Executive Director | 11.2yrs | CN¥371.00k | Veri yok | |
| Independent Non-Executive Director | 10.8yrs | CN¥371.00k | Veri yok | |
| Independent Non-Executive Director | 1.6yrs | CN¥202.00k | Veri yok |
8.7yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 460 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.7 yıldır).